Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac

Evotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a €40m joint venture to fight Antimicrobial Resistance (AMR).

Read more

Urovant Sciences cashes in $75m in licence deal from Pierre Fabre

French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe.

Read more

CureVac NV sues BioNTech for IP infringement

German mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents.

Read more

French Ipsen falls after Epizyme take-over announcement

Shares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m.

Read more

TWB announces winners in industrial biotech start-up contest

At the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth €50,000.

Read more

BIONTech breaks ground for manufacturing site in Rwanda

BioNTech SE has announced it is going to ship the first containers for mRNA malaria vaccine production from this year’s end toKigall.

Read more

Cannabis players Canify AS and Bavaria Weed merge to form Canify AG

In an effort to become a major player in Europe’s growing pharmaceutical-grade cannabis market, Danish Canify AS and Bavaria Weed GmbH merge to form Canify AG.  

Read more

Unilever launches $120m venture with Genomatica

Under the $120m deal, Genomatica and Unilever will scale plant- and waste-based alternative to palm oil and fossil fuels.

Read more

Roche obtains special authorisation for bispecific antibody

Roche obtained from European Medicine Agency (EMA) a special authorization (conditional approval) for new bispecific antibody Lunsumio for treatment of relapsed or refractory follicular (R/R) lymphoma (FL) – a B-cell cancer. Data for authorization are based on a survey from a phase I/II trail. The high unmet need of this indication led to that early decision, it is said.

Read more

French ImCheck get´s a USD103m check by Pfizer and a pack of VCs

ImCheck Therapeutics located in Marseille, France, announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. Kurma Partners, Eurazeo, Gimv, Pfizer, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Pureos Bioventures, Agent Capital and Alexandria Venture Investments are invested already. Invus and The Leukemia & Lymphoma
Society Therapy Acceleration Program also joined the round as new investors.

Read more